SI1639007T1 - Pasti VEGF in njihove terapevtske uporabe - Google Patents

Pasti VEGF in njihove terapevtske uporabe

Info

Publication number
SI1639007T1
SI1639007T1 SI200431151T SI200431151T SI1639007T1 SI 1639007 T1 SI1639007 T1 SI 1639007T1 SI 200431151 T SI200431151 T SI 200431151T SI 200431151 T SI200431151 T SI 200431151T SI 1639007 T1 SI1639007 T1 SI 1639007T1
Authority
SI
Slovenia
Prior art keywords
therapeutic uses
vegf traps
vegf
traps
therapeutic
Prior art date
Application number
SI200431151T
Other languages
English (en)
Inventor
Thomas J Daly
James P Fandl
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33552268&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1639007(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SI1639007T1 publication Critical patent/SI1639007T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SI200431151T 2003-06-30 2004-06-29 Pasti VEGF in njihove terapevtske uporabe SI1639007T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/609,775 US7087411B2 (en) 1999-06-08 2003-06-30 Fusion protein capable of binding VEGF
EP04777335A EP1639007B1 (en) 2003-06-30 2004-06-29 Vegf traps and therapeutic uses thereof
PCT/US2004/021059 WO2005000895A2 (en) 2003-06-30 2004-06-29 Vegf traps and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
SI1639007T1 true SI1639007T1 (sl) 2009-08-31

Family

ID=33552268

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200431581T SI1947118T1 (sl) 2003-06-30 2004-06-29 VEGF pasti in njihove terapevtske uporabe
SI200431151T SI1639007T1 (sl) 2003-06-30 2004-06-29 Pasti VEGF in njihove terapevtske uporabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200431581T SI1947118T1 (sl) 2003-06-30 2004-06-29 VEGF pasti in njihove terapevtske uporabe

Country Status (29)

Country Link
US (4) US7087411B2 (sl)
EP (2) EP1639007B1 (sl)
JP (2) JP2007528708A (sl)
KR (1) KR101131429B1 (sl)
CN (1) CN1816566B (sl)
AR (1) AR044938A1 (sl)
AT (2) ATE427962T1 (sl)
AU (1) AU2004252175B2 (sl)
BR (1) BRPI0412125A (sl)
CA (1) CA2529660C (sl)
CY (2) CY1109204T1 (sl)
DE (2) DE602004029833D1 (sl)
DK (2) DK1947118T3 (sl)
ES (2) ES2323468T3 (sl)
HK (1) HK1082511A1 (sl)
IL (2) IL172404A (sl)
MX (1) MXPA05013641A (sl)
MY (1) MY154826A (sl)
NO (1) NO339766B1 (sl)
NZ (2) NZ544569A (sl)
PL (2) PL1639007T3 (sl)
PT (2) PT1947118E (sl)
RU (1) RU2376373C2 (sl)
SI (2) SI1947118T1 (sl)
TW (1) TWI330197B (sl)
UA (2) UA90657C2 (sl)
UY (1) UY28396A1 (sl)
WO (1) WO2005000895A2 (sl)
ZA (1) ZA200600157B (sl)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005069906A2 (en) * 2004-01-16 2005-08-04 Yale University Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
WO2005087808A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
WO2005123104A2 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
ES2407859T3 (es) 2004-09-13 2013-06-14 Genzyme Corporation Construcciones multiméricas.
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20080107648A1 (en) * 2005-12-16 2008-05-08 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with DII4 antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
CA2597247A1 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US20060217311A1 (en) * 2005-03-25 2006-09-28 Daniel Dix VEGF antagonist formulations
JP2009504679A (ja) * 2005-08-12 2009-02-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆアンタゴニストを用いて疾患を処置する方法
US8329866B2 (en) * 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2008005290A2 (en) * 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
RU2549676C2 (ru) 2007-06-01 2015-04-27 Юниверсити Оф Мэрилэнд, Балтимор СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
EP2727996A1 (en) * 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103154036B (zh) 2010-07-28 2016-05-11 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
HUE035554T2 (en) 2010-08-06 2018-05-02 Genzyme Corp VEGF antagonist compositions and their uses
WO2012064792A2 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
AU2012205599B2 (en) 2011-01-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP3415533A1 (en) 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
US9701731B2 (en) 2011-08-19 2017-07-11 Children's Medical Center Corporation VEGF-binding protein for blockade of angiogenesis
JP6271432B2 (ja) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥｒｂＢ３抗体およびその使用
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CN103957898B (zh) 2011-11-18 2016-02-24 瑞泽恩制药公司 聚合物蛋白微粒
CA2857168C (en) * 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
NZ631565A (en) 2012-03-14 2016-07-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
CN104718223A (zh) 2012-08-20 2015-06-17 格利克尼克股份有限公司 具有抗原结合和多价FCγ受体结合活性的分子
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US20140134189A1 (en) 2012-11-13 2014-05-15 Regeneron Pharmaceuticals, Inc. Anti-prokineticin receptor (prokr) antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP2956476B1 (en) * 2013-02-18 2019-12-25 Vegenics Pty Limited Ligand binding molecules and uses thereof
CA2904644C (en) 2013-03-14 2022-09-20 Regeneron Pharmaceuticals, Inc. Human antibodies to grem1
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
CN105431204A (zh) 2013-07-12 2016-03-23 奥普索特克公司 用于治疗或预防眼科病的方法
KR102060187B1 (ko) 2013-07-19 2019-12-27 삼성전자주식회사 Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
WO2015058369A1 (en) * 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JP6632984B2 (ja) 2014-03-11 2020-01-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ＥＧＦＲｖＩＩＩ抗体およびその使用
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
DK3180018T3 (da) 2014-08-12 2019-10-28 Massachusetts Inst Technology Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
DK3221359T3 (da) 2014-11-17 2020-06-22 Regeneron Pharma Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
TW202336236A (zh) 2015-03-27 2023-09-16 美商再生元醫藥公司 偵測生物污染物之組成物及方法
EP3273998B1 (en) 2015-03-27 2019-09-04 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
AU2016253005B2 (en) * 2015-04-23 2020-07-09 Hemanext Inc. Anaerobic blood storage containers
PL3294775T3 (pl) * 2015-05-12 2021-12-13 Regeneron Pharmaceuticals, Inc. Oznaczanie czystości białka multimerycznego
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017053856A1 (en) 2015-09-23 2017-03-30 Regeneron Pharmaceuticals, Inc. Optimized anti-cd3 bispecific antibodies and uses thereof
EP3355910A4 (en) 2015-09-28 2019-08-28 East Carolina University ALUMINUM-BASED ADJUVANTS FOR TOLEROGENIC VACCINATION
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017070866A1 (zh) * 2015-10-28 2017-05-04 黄志清 一种抗血管内皮生长因子的氧化石墨烯与其用途
CA3005391A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CA3137326C (en) 2015-12-03 2024-01-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitor to treat macular degeneration in a patient population
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2016369557B2 (en) 2015-12-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
HRP20231156T1 (hr) 2015-12-22 2024-01-05 Regeneron Pharmaceuticals, Inc. Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2017211120C1 (en) 2016-01-25 2021-10-07 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
US20190142975A1 (en) 2016-04-29 2019-05-16 Adverum Biotechnologies, Inc. Evasion of neutralizing antibodies by a recombinant adeno-associated virus
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
WO2017214321A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
SG11201900192VA (en) 2016-07-29 2019-02-27 Regeneron Pharma Assembly line with integrated electronic visual inspection
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
FI3761035T3 (fi) 2016-08-18 2024-03-18 Regeneron Pharma Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP7066691B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体
US10772972B2 (en) 2016-09-23 2020-09-15 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
WO2018068012A1 (en) 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
AU2017350807B2 (en) 2016-10-25 2022-07-07 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
CA3044534A1 (en) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
AU2018207303A1 (en) 2017-01-10 2019-07-25 xCella Biosciences, Inc. Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
SG11201907653QA (en) 2017-03-17 2019-09-27 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CA3062418A1 (en) 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
BR112019027211A2 (pt) 2017-06-28 2020-06-30 Regeneron Pharmaceuticals, Inc. proteínas de ligação ao antígeno do papilomavírus anti-humano (hpv) e seus métodos de uso
EP3967765A1 (en) 2017-07-06 2022-03-16 FrieslandCampina Nederland B.V. Cell culture process for making a glycoprotein
JP7304846B2 (ja) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ８抗体およびその使用
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
WO2019079494A1 (en) * 2017-10-18 2019-04-25 Regenxbio, Inc. TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION
HRP20221335T1 (hr) 2017-11-30 2022-12-23 Regeneron Pharmaceuticals, Inc. Upotreba antagonista vegf za liječenje angiogenih očnih poremećaja
CA3084155A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
US20190194298A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
KR20200115485A (ko) 2018-01-31 2020-10-07 리제너론 파마슈티칼스 인코포레이티드 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
TWI825066B (zh) 2018-02-01 2023-12-11 美商再生元醫藥公司 治療性單株抗體之品質屬性的定量及模型化
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
PL3768709T3 (pl) 2018-03-19 2024-05-20 Regeneron Pharmaceuticals, Inc. Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki
WO2019197676A1 (en) 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
TWI814812B (zh) 2018-05-02 2023-09-11 美商里珍納龍藥品有限公司 用於評估生化過濾器的適合性的方法
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
SG11202010684YA (en) 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
TW202005985A (zh) 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020036845A1 (en) 2018-08-13 2020-02-20 Regeneron Pharmaceuticals, Inc. Therapeutic protein selection in simulated in vivo conditions
SG11202011969WA (en) 2018-08-30 2020-12-30 Regeneron Pharma Methods for characterizing protein complexes
EP3870602A1 (en) 2018-10-23 2021-09-01 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
HUE061783T2 (hu) 2019-01-16 2023-08-28 Regeneron Pharma Módszerek diszulfidkötések jellemzésére
EP3914914A1 (en) 2019-01-25 2021-12-01 Regeneron Pharmaceuticals, Inc. Protein a chromatography - electrospray ionization mass spectrometer
BR112021014427A2 (pt) 2019-01-25 2021-09-28 Regeneron Pharmaceuticals, Inc. Quantificação e identificação de dímeros em coformulações
CN113412121A (zh) 2019-02-12 2021-09-17 瑞泽恩制药公司 使用双特异性抗体结合补体和靶抗原的组合物和方法
MX2021010114A (es) 2019-02-21 2021-12-10 Regeneron Pharma Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met.
KR20210136071A (ko) 2019-03-06 2021-11-16 리제너론 파아마슈티컬스, 인크. 암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제
CN114144672A (zh) 2019-04-17 2022-03-04 瑞泽恩制药公司 宿主细胞蛋白质的鉴定
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US20200363400A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Competitive Ligand Binding Assays
EP3969040A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2022537019A (ja) 2019-06-21 2022-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
WO2020257604A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
EP4034870A1 (en) 2019-09-24 2022-08-03 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108548A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
PE20221790A1 (es) 2019-12-06 2022-11-25 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma
KR20220110555A (ko) * 2019-12-06 2022-08-08 리제너론 파마슈티칼스 인코포레이티드 Vegf 미니-트랩 및 그의 사용 방법
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
US20230060095A1 (en) 2020-01-24 2023-02-23 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
WO2021174151A1 (en) 2020-02-27 2021-09-02 Regeneron Pharmaceuticals, Inc. Methods of reducing polysorbate degradation in drug formulations
JP2023515941A (ja) 2020-02-28 2023-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｅｒ２に結合する二重特異性抗原結合分子およびその使用方法
EP4114859A1 (en) 2020-03-06 2023-01-11 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
EP4127729A1 (en) 2020-03-30 2023-02-08 Regeneron Pharmaceuticals, Inc. Methods for characterizing low-abundance host cell proteins
KR20230008830A (ko) * 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
JP2023530187A (ja) 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
IL299153A (en) 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
EP4183415A4 (en) 2020-07-16 2024-07-17 Raqualia Pharma Inc TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4222171A1 (en) 2020-10-02 2023-08-09 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
IL301702A (en) 2020-10-22 2023-05-01 Regeneron Pharma Anti-FGFR2 antibodies and methods of using them
AU2021377185A1 (en) 2020-11-10 2023-06-08 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
AU2021385363A1 (en) 2020-11-25 2023-06-08 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
AU2021401301A1 (en) 2020-12-17 2023-08-03 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
US12030935B2 (en) 2021-01-25 2024-07-09 Regeneron Pharmaceuticals, Inc. Anti-PDGF-B antibodies and pharmaceutical composition thereof
US20240034796A1 (en) 2021-02-04 2024-02-01 Genuv Inc. Anti-pd-1 antibody and use thereof
MX2023009279A (es) 2021-02-11 2023-10-02 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
CA3170733A1 (en) 2021-02-23 2022-09-01 Petra RIETSCHEL Methods of treating lung cancer by administering a pd-1 inhibitor
TW202246325A (zh) 2021-03-03 2022-12-01 美商再生元醫藥公司 用於定量及修飾蛋白質黏度之系統及方法
WO2022204672A1 (en) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
WO2022204728A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
TW202313096A (zh) 2021-05-28 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 衣殼變異的重組腺相關病毒及其應用
MX2023014246A (es) 2021-06-01 2024-01-17 Regeneron Pharma Ensayos y reactivos de microchips de electroforesis capilar.
KR20240024061A (ko) 2021-06-22 2024-02-23 리제너론 파마슈티칼스 인코포레이티드 항-EGFRvIII 항체 약물 접합체 및 이의 용도
US20230045769A1 (en) 2021-07-13 2023-02-09 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based strategy for determining product-related variants of a biologic
WO2023287821A1 (en) 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
EP4402475A1 (en) 2021-09-14 2024-07-24 Regeneron Pharmaceuticals, Inc. Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic
AU2022354864A1 (en) 2021-09-28 2024-03-07 Regeneron Pharmaceuticals, Inc. Assays to quantitate drug and target concentrations
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的***及方法
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
KR20240095300A (ko) 2021-11-01 2024-06-25 리제너론 파아마슈티컬스, 인크. Ms-기반 프로테오믹스를 위하여 디술피드 스크램블링을 방지하는 방법
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230235089A1 (en) 2021-11-24 2023-07-27 Regeneron Pharmaceuticals, Inc. Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies
IL313159A (en) 2021-12-01 2024-07-01 Kadmon Corp Llc B7-H4 antibodies and ANTI-B7-H4 antibody/IL-15 fusion proteins
CA3241734A1 (en) 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
US20240148867A1 (en) 2022-10-31 2024-05-09 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024118785A2 (en) 2022-11-30 2024-06-06 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024137731A2 (en) 2022-12-21 2024-06-27 Genzyme Corporation Anti‑pd‑1×4‑1bb binding proteins
WO2024138000A1 (en) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DE69633175T2 (de) * 1995-05-23 2005-08-11 Morphosys Ag Multimere proteine
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
WO1997042319A1 (fr) * 1996-05-02 1997-11-13 Mochida Pharmaceutical Co., Ltd. NOUVEAUX DERIVES DE L'ANTIGENE Fas
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
EP0928203B1 (en) 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
NZ515913A (en) 1999-06-08 2004-01-30 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF

Also Published As

Publication number Publication date
EP1639007A2 (en) 2006-03-29
IL172404A (en) 2011-12-29
PL1947118T3 (pl) 2011-05-31
CY1109204T1 (el) 2014-07-02
US20040014667A1 (en) 2004-01-22
DE602004029833D1 (de) 2010-12-09
CA2529660C (en) 2013-08-06
US7087411B2 (en) 2006-08-08
EP1639007B1 (en) 2009-04-08
UA90657C2 (ru) 2010-05-25
CN1816566B (zh) 2011-01-12
CN1816566A (zh) 2006-08-09
NO20060483L (no) 2006-03-28
ATE427962T1 (de) 2009-04-15
ZA200600157B (en) 2007-04-25
ATE486091T1 (de) 2010-11-15
MY154826A (en) 2015-07-31
AU2004252175B2 (en) 2010-07-22
PT1947118E (pt) 2010-12-02
DK1947118T3 (da) 2011-02-07
KR101131429B1 (ko) 2012-07-27
NZ544569A (en) 2008-12-24
KR20060096184A (ko) 2006-09-08
DE602004020474D1 (de) 2009-05-20
HK1082511A1 (en) 2006-06-09
AU2004252175A1 (en) 2005-01-06
ES2323468T3 (es) 2009-07-16
RU2376373C2 (ru) 2009-12-20
BRPI0412125A (pt) 2006-08-15
UA105625C2 (uk) 2014-06-10
TWI330197B (en) 2010-09-11
NZ572107A (en) 2009-01-31
JP2007528708A (ja) 2007-10-18
US7635474B2 (en) 2009-12-22
SI1947118T1 (sl) 2011-02-28
DK1639007T3 (da) 2009-06-08
CY1111605T1 (el) 2015-10-07
US20050043236A1 (en) 2005-02-24
US7972598B2 (en) 2011-07-05
IL204984A (en) 2011-12-29
PL1639007T3 (pl) 2009-11-30
CA2529660A1 (en) 2005-01-06
WO2005000895A3 (en) 2005-09-15
WO2005000895A2 (en) 2005-01-06
IL172404A0 (en) 2006-04-10
TW200513532A (en) 2005-04-16
ES2354847T3 (es) 2011-03-18
JP2010246557A (ja) 2010-11-04
EP1947118A1 (en) 2008-07-23
NO339766B1 (no) 2017-01-30
EP1947118B1 (en) 2010-10-27
UY28396A1 (es) 2004-11-08
US20100087632A1 (en) 2010-04-08
AR044938A1 (es) 2005-10-12
PT1639007E (pt) 2009-06-04
US7279159B2 (en) 2007-10-09
MXPA05013641A (es) 2006-02-24
US20090062200A1 (en) 2009-03-05
RU2006102497A (ru) 2006-06-10

Similar Documents

Publication Publication Date Title
IL172404A0 (en) Vegf traps and therapeutic uses thereof
EP1691718A4 (en) THERAPEUTIC MICROTEILS
EP1781689A4 (en) CONJUGATES AND THEIR THERAPEUTIC APPLICATIONS
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL182498A0 (en) Therapeutic furopyrimidines and thienopyrimidines
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
GB0307918D0 (en) Therapeutic use
GB0415112D0 (en) Therapeutic device
EP1682136A4 (en) THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
EP1838288A4 (en) THERAPEUTIC MATERIALS AND METHODS
GB0300416D0 (en) Massage device
ATA13602003A (de) Therapeutisches behandlungsgerät
GB0308382D0 (en) Therapeutic methods and means
GB0407382D0 (en) Therapeutic methods and means
GB2403917B (en) Exercise methods and devices
EP1701736A4 (en) THERAPEUTIC AGENTS AND ITS USES
EP1683554A4 (en) GAME SOFTWARE AND GAME DEVICE
GB0419240D0 (en) Therapeutic device
GB0313625D0 (en) Therapeutic and assay methods
DE602004009262D1 (de) Elektrotherapievorrichtung
GB0327844D0 (en) Therapeutic methods and means
GB0300146D0 (en) Therapeutic device
DE502004009352D1 (de) Gerbstoffe und konservierungsmittel
ITMI20031129A1 (it) Dispositivo e procedimento di stimolazione propriocettiva.